<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940521</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2018-02/PC-01</org_study_id>
    <nct_id>NCT03940521</nct_id>
  </id_info>
  <brief_title>Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment</brief_title>
  <acronym>RESERVIH32</acronym>
  <official_title>Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Génétique Moléculaire de Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The authors hypothesize that there is a correlation between the percentage of CD4+ T cells
      expressing CD32a and/or X and the quantity of DNA found in peripheral blood mononuclear cells
      in patients infected with HIV-1. Also, that there is a correlation between expression of
      CD32a and/or X and proviral load.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of CD4+ T cells expressing CD32 alone</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of CD4+ T cells expressing X alone</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of CD4+ T cells expressing both CD32 and X</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of proviral load</measure>
    <time_frame>Day 0</time_frame>
    <description>Quantitative PCR; number of copies of HIV-1 DNA per million peripheral blood mononuclear cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of infection prior to treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Year treatment commenced</measure>
    <time_frame>Day 0</time_frame>
    <description>Year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-therapeutic CD4 + T cell count</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of CD4+ T cells/ microL blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-therapeutic viremia</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of copies of HIV-1 RNA/ml plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ T cells over previous 2 years</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of CD4+ T cells/microL blood lost per year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ T cells prior to treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of CD4+ T cells/microL blood lost per year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4+ T cells during treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of CD4+ T cells/microL blood lost per year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viremia at inclusion into the study</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of copies of HIV-1 RNA/ml plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viremia during the 2 previous years</measure>
    <time_frame>Day 0</time_frame>
    <description>Number of copies of HIV-1 RNA/ml plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual immune activation at inclusion into the study</measure>
    <time_frame>Day 0</time_frame>
    <description>CD4/CD8 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual immune activation during the previous 2 years</measure>
    <time_frame>Day 0</time_frame>
    <description>CD4/CD8 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nature of current treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>Family of molecule</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Co-infection with hepatitis C virus</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Co-infection with hepatitis B virus</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Co-infection with Cytomegalovirus</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Co-infection with Epstein-Barr virus</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">48</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>HIV-A infected patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bioclinical evaluation</intervention_name>
    <description>50-100ml blood extracted for flow cytometry and qPCR</description>
    <arm_group_label>HIV-A infected patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with aviremic HIV-1 undergoing antiretroviral treatment for at least 2 years.
        Patients will be divided into 3 groups according to pre-therapeutic CD4+ T cell levels:

          -  &quot;Low&quot; (n=16): &lt; 200 CD4+ T cells/mm3,

          -  &quot;Medium&quot; (n=16): 200 to 500 CD4+ T cells/mm3,

          -  &quot;High&quot; (n=16): &gt;500 CD4+ T cells/mm3.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient infected with aviremic HIV-1 (&lt;20 copies of HIV-1 RNA/ml plasma) undergoing
             antiretroviral treatment for at least 2 years

          -  Patient has known duration of infection and treatment

          -  Patient has known pretherapeutic CD4+ T cell count and viremia

          -  Patient has known CD4+ T cell count, residual viremia and CD4/CD8 ratio for previous 2
             years

          -  Patient weighs at least 56kg

          -  The patient is not opposed to their inclusion in the study

          -  The patient must be a member or beneficiary of a health insurance plan

          -  Patient at least 18 years old

        Exclusion Criteria:

          -  Patient has an acute infection

          -  The subject has already been included in the study or is in a period of exclusion
             determined by a previous study

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship

          -  Patient is pregnant, parturient or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Corbeau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Corbeau, MD</last_name>
    <phone>0607231635</phone>
    <email>Pierre.corbeau@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Corbeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudine Barbuat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert Sorro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc Maulboussin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Rouanet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier Laureillard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

